Abstract
A low pressure plasma process based on plasma deposition has been used to develop a drug delivery strategy. In this study, a drug delivery system based on different layers of plasma co-polymerized Poly ε-caprolactone-Polyethylene glycol (PCL-PEG) co-polymers was deposited on biocompatible substrates. Cis-platinum (118 μgm/cm2) was used as an anti-cancer drug and incorporated for local delivery of the chemotherapeutic agent. The co-polymer layers and their interaction with cancer cells were analyzed by scanning electron microscopy. Our study showed that the plasma-PCL-PEG coated cellophane membranes, in which the drug, was included did not modify the flexibility and appearance of the membranes. This system was actively investigated as an alternative method of controlling localized delivery of drug in vivo. The loading of the anti-cancer drug was investigated by UV-VIS spectroscopy and its release from plasma deposited implants against BALB/c mice liver tissues were analyzed through histological examination and apoptosis by TUNEL assay. The histological examination of liver tissues revealed that when the plasma-modified membranes encapsulated the cis-platinum, the Glisson's capsule and liver parenchyma were damaged. In all cases, inflammatory tissues and fibrosis cells were observed in contact zones between the implant and the liver parenchyma. In conclusion, low pressure plasma deposited uniform nano-layers of the co-polymers can be used for controlled release of the drug in vivo.
Highlights
In the past several years interest in platinum drugs has increased due to their successful administration for the treatment of most disseminated cancers [1]
A drug delivery system based on different layers of plasma co-polymerized Poly ε-caprolactone-Polyethylene glycol (PCL-PEG) co-polymers was deposited on biocompatible substrates
In this study we described the in vivo local drug release efficacy of the low pressure plasma polymerized PCL-co-PEG encapsulated cis-platinum implants as biocompatible and biodegradable drug carriers
Summary
In the past several years interest in platinum drugs has increased due to their successful administration for the treatment of most disseminated cancers [1]. After 24 hrs of clinical administration of cis-platinum, it has been noticed that more than 65% of the platinum in the blood was protein bound, leading to severe side effects of cis-platinum treatment and less therapeutic efficacy [7] and resistance over the course of medication [8]. In order to overcome these therapeutic limitations by www.impactjournals.com/oncotarget cis-platinum treatment and other anticancer drugs, there is a clear incentive to develop new strategies for efficient, systematic and controlled release of cis-platinum for oncology
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
